Back to today’s briefing

Story perspectives

$700 Million Opioid Settlement Approved, Giants Deny Wrongdoing

3/7/2025

24 5

Summary

Story summary

A landmark $700 million class-action settlement has been greenlit by a judge, targeting opioid giants like AmerisourceBergen and Johnson & Johnson. While they will allocate $651 million to healthcare facilities and $49 million for life-saving Naloxone, they continue to deny any wrongdoing amid allegations of misleading practices and overprescribing. The exact legal fees remain uncertain.

1 of 1

Story summary

A landmark $700 million class-action settlement has been greenlit by a judge, targeting opioid giants like AmerisourceBergen and Johnson & Johnson. While they will allocate $651 million to healthcare facilities and $49 million for life-saving Naloxone, they continue to deny any wrongdoing amid allegations of misleading practices and overprescribing. The exact legal fees remain uncertain.